---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-21-024376"
form_type: "8-K"
ticker: "PTIX"
cik: "0001022899"
company_name: "Protagenic Therapeutics, Inc.new"
filed_at: "2021-10-01T23:59:59+00:00"
generated_at: "2026-06-28T23:42:19.530863+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Protagenic Therapeutics stockholders approve classified board structure; directors re-elected

## Summary
- At Sep 29 annual meeting, all six director nominees elected with votes ranging from 8.37M to 8.88M for each.
- Stockholders approved classified board amendment (8.82M for, 150.9K against); filed with Delaware on Oct 1, 2021.
- Board classified into three classes: Class I (Buell, Stein) term expiring 2022, Class II (Barrage, Silverman) 2023, Class III (Armen, Corvese) 2024.
- MaloneBailey LLP ratified as independent auditor for FY2021 (10.60M for, 2.8K against).

## SEC filing metadata
- accession: 0001493152-21-024376
- form_type: 8-K
- ticker: PTIX
- cik: 0001022899
- company_name: Protagenic Therapeutics, Inc.new
- filed_at: 2021-10-01T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1022899/000149315221024376/0001493152-21-024376-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1022899/000149315221024376/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-21-024376
- JSON: https://secwatch.observer/filing/0001493152-21-024376.json
- Plain text: https://secwatch.observer/filing/0001493152-21-024376.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.